|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B virus infection of transplanted human hepatocytes causes a biochemical and histological hepatitis in immunocompetent rats显示文摘AIM: To characterize the host response to hepatitis B virus (HBV) infection in human hepatocytes transplanted into immunocompetent rodent rats tolerized by, and transplanted with primary human hepatocytes.METHODS: One week after the transplantation, rats were inoculated with HBV, and viral gene expression, replication,and host response was monitored.RESULTS: HBV DNA was detectable in serum for at least 60 days. HBsAg levels rose steadily for 3 weeks postinoculation and then plateaued at a level of about 0.6 pg/mi. HBV RNA was also found in liver at levels that remained constant through the time course. Immunofluorescence revealed clusters of hepatocytes that stained positive for HBcAg. The presence of HBV covalently closed circular DNA (cccDNA) in liver was demonstrated using nuclease digestion of single-stranded DNA followed by PCR. Serum ALT levels rose and reached a peak level of 180 IU/L on day 18, but remained elevated for 60 days. Histology revealed a progressive predominantly mononuclear lobular hepatitis.CONCLUSION: These data indicate that human hepatocytestransplanted into rats rendered tolerant to these cells, when infected by HBV, results in biochemical as well as histological evidence of hepatitis that accompanies viral gene expression,and DNA replication. | Catherine H.Wu Edwin C.Ouyang Cherie Walton Kittichai Promrat Faripour Forouhar George Y. Wu | 2003 | World Journal of Gastroenterology2003，9，5： | 19 |
| 2 | Clinical implications,diagnosis,and management of diabetes in patients with chronic liver diseases显示文摘Diabetes mellitus(DM)negatively affects the development and progression of chronic liver diseases(CLD)of various etiologies.Concurrent DM and CLD are also associated with worse clinical outcomes with respect to mortality,the occurrence of hepatic decompensation,and the development of hepatocellular carcinoma(HCC).Unfortunately,early diagnosis and optimal treatment of DM can be challenging,due to the lack of established clinical guidelines as well as the medical complexity of this patient population.We conducted an exploratory review of relevant literature to provide an up-to-date review for internists and hepatologists caring for this patient population.We reviewed the epidemiological and pathophysiological associations between DM and CLD,the impact of insulin resistance on the progression and manifestations of CLD,the pathogenesis of hepatogenic diabetes,as well as the practical challenges in diagnosis and monitoring of DM in this patient population.We also reviewed the latest clinical evidence on various pharmacological antihyperglycemic therapies with an emphasis on liver disease-related clinical outcomes.Finally,we proposed an algorithm for managing DM in patients with CLD and discussed the clinical and research questions that remain to be addressed. | Waihong Chung Kittichai Promrat Jack Wands | 2020 | World Journal of Hepatology2020，12，9： | 3 |
| 3 | Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis显示文摘 | Kittichai Promrat David E. Kleiner Heather M. Niemeier Elizabeth Jackvony Marie Kearns Jack R. Wands Joseph L. Fava Rena R. Wing | 2009 | Hepatology2009，，1： | 2 |
| 4 | Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population:NHANES database显示文摘BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is the most common chronic liver disease,affecting over 30% of the United States population.Early patient identification using a simple method is highly desirable.AIM To create machine learning models for predicting NAFLD in the general United States population.METHODS Using the NHANES 1988-1994.Thirty NAFLD-related factors were included.The dataset was divided into the training(70%)and testing(30%)datasets.Twentyfour machine learning algorithms were applied to the training dataset.The bestperforming models and another interpretable model(i.e.,coarse trees)were tested using the testing dataset.RESULTS There were 3235 participants(n=3235)that met the inclusion criteria.In the training phase,the ensemble of random undersampling(RUS)boosted trees had the highest F1(0.53).In the testing phase,we compared selective machine learning models and NAFLD indices.Based on F1,the ensemble of RUS boosted trees remained the top performer(accuracy 71.1%and F10.56)followed by the fatty liver index(accuracy 68.8% and F10.52).A simple model(coarse trees)had an accuracy of 74.9% and an F1 of 0.33.CONCLUSION Not every machine learning model is complex.Using a simpler model such as coarse trees,we can create an interpretable model for predicting NAFLD with only two predictors:fasting C-peptide and waist circumference.Although the simpler model does not have the best performance,its simplicity is useful in clinical practice. | Amporn Atsawarungruangkit Passisd Laoveeravat Kittichai Promrat | 2021 | World Journal of Hepatology2021，13，10： | 2 |
| 5 | Randomized controlled trial testing the effects of wetght loss on nonalcoholic steatohepatitis 显示文摘 | Promrat K K1 einer DE Niemeier HM | 2010 | Hepatology2010，51，1： | 1 |
| 6 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，1： | 1 |
| 7 | Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis显示文摘 | Promrat K Kleiner DE Niemeier HM | | 0，，01： | 1 |
| 8 | A pilot study of pioglita zone treatment for nonalcoholic steatohepati显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，： | 1 |
| 9 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis显示文摘 | Promrat K LutchmanG Uwaifo GI | 2004 | Hepatology2004，39，1： | 1 |
| 10 | Random- ized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis 显示文摘 | Promrat K Kleiner DE Niemeier HM | 2010 | Hepatology2010，51，1： | 1 |
| 11 | A pilot study of piogli- tazone treatment for nonalcoholic steatohepatitis显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，1： | 1 |
| 12 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis 显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，1： | 1 |
| 13 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis显示文摘 | Promrat K Lutchman G Uwaifo GI | | 0，，： | 1 |
| 14 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis显示文摘 | PROMRAT K LUTCHMAN G UWAIFO G I | 2004 | Hepatology2004，39，1： | 1 |
| 15 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis 显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，1： | 1 |
| 16 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，1： | 1 |
| 17 | Randomized controlledtrial testing the effects of weight loss on nonalcoholic steatohepatitis显示文摘 | Promrat K Kleiner DE Niemeier HM | 2010 | Hepatology2010，51，1： | 1 |
| 18 | A pilot study of pioglita zone treatment for nonalcoholic steatohepati 显示文摘 | Promrat K Lutchman G Uwaifo GI | 2004 | Hepatology2004，39，： | 1 |
| 19 | Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement显示文摘 | LUTCHMAN G PROMRAT K KLEINER D E | 2006 | Clin Gastroenterol Hepatol2006，4，8： | 1 |
| 20 | A pilot sludy ofpioglitazone treatment for nonalcoholic steatohepafitis显示文摘 | Promrat K Lutehman G Uwaifo G I | 2004 | Hepatology2004，39，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员